UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Lancet neurology, ISSN 1474-4422, 2015, Volume 14, Issue 9, pp. 926 - 944
Neurology | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Learning | Clinical Trials as Topic - trends | Risk Reduction Behavior | Alzheimer Disease - prevention & control | Humans | Risk Factors | Alzheimer Disease - therapy | Antioxidants - administration & dosage | Forecasting | Prevention | Clinical trials | Alzheimer's disease | Studies | Cognition & reasoning | Alzheimers disease | Pharmaceutical industry | Dementia | Index Medicus
Journal Article
BMC medicine, ISSN 1741-7015, 02/2009, Volume 7, Issue 1, pp. 7 - 7
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Alzheimer Disease - drug therapy | Clinical Trials as Topic | United States | Humans | Care and treatment | Amyloid beta-protein | Causes of | Diagnosis | Research | Alzheimer's disease | Health aspects | Index Medicus
Journal Article
Lancet neurology, ISSN 1474-4422, 2013, Volume 12, Issue 2, pp. 207 - 216
Neurology | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Alzheimer Disease - physiopathology | Models, Biological | Cognition Disorders - etiology | Humans | Amyloid beta-Peptides - cerebrospinal fluid | tau Proteins - cerebrospinal fluid | Biomarkers - cerebrospinal fluid | Alzheimer Disease - cerebrospinal fluid | Nonlinear Dynamics | Alzheimer Disease - pathology | Index Medicus | Neurodegenerative diseases | Tau protein | Brain stem | biomarkers | Cognitive ability | Evolution | beta -Amyloid | Alzheimer's disease
Journal Article
Lancet neurology, ISSN 1474-4422, 2010, Volume 9, Issue 1, pp. 119 - 128
Neurology | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Brain - diagnostic imaging | Apolipoprotein E4 - genetics | Humans | tau Proteins - metabolism | Positron-Emission Tomography | Alzheimer Disease - pathology | Aging - genetics | Time Factors | Amyloid beta-Peptides - metabolism | Amyloid beta-Peptides - cerebrospinal fluid | Biomarkers - metabolism | Alzheimer Disease - physiopathology | Cognition Disorders - physiopathology | Plaque, Amyloid - pathology | Signal Transduction | Brain - physiopathology | Cognition Disorders - pathology | Cognition Disorders - genetics | tau Proteins - cerebrospinal fluid | Disease Progression | Aging - pathology | Plaque, Amyloid - genetics | Magnetic Resonance Imaging | Aging - physiology | Brain - pathology | Plaque, Amyloid - metabolism | Biomarkers - cerebrospinal fluid | Models, Neurological | Alzheimer Disease - genetics | Index Medicus
Journal Article
Neurology, ISSN 0028-3878, 01/2018, Volume 90, Issue 3, pp. 145 - 145
Journal Article
The New England journal of medicine, ISSN 0028-4793, 01/2014, Volume 370, Issue 4, pp. 311 - 321
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Neurology | Organic mental disorders. Neuropsychology | General aspects | Psychology. Psychoanalysis. Psychiatry | Adult and adolescent clinical studies | Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases | Psychopathology. Psychiatry | Biological and medical sciences | Medical sciences | Severity of Illness Index | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Humans | Alzheimer Disease - drug therapy | Male | tau Proteins - cerebrospinal fluid | Biomarkers - blood | Alzheimer Disease - cerebrospinal fluid | Cognition - drug effects | Amyloid beta-Peptides - blood | Activities of Daily Living | Neuropsychological Tests | Apolipoproteins E - blood | Apolipoproteins E - genetics | Treatment Failure | Intention to Treat Analysis | Aged, 80 and over | Amyloid beta-Peptides - cerebrospinal fluid | Female | Aged | Biomarkers - cerebrospinal fluid | Alzheimer Disease - blood | Solanezumab | Care and treatment | Research | Drug therapy | Alzheimer's disease | Neuroimaging | Edema | Activities of daily living | Neurodegenerative diseases | Cognitive ability | Clinical trials | Data processing | Hemorrhage | Quality of life | Studies | Neurofibrillary tangles | Gliosis | Older people | Monoclonal antibodies | Alzheimers disease | Plaques | Index Medicus | Abridged Index Medicus
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 06/2017, Volume 317, Issue 22, pp. 2305 - 2316
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Brain - diagnostic imaging | Mental Recall | Follow-Up Studies | United States | Humans | Male | Cognition | Alzheimer Disease - cerebrospinal fluid | Brain - metabolism | Positron Emission Tomography Computed Tomography | Canada | Time Factors | Amyloid beta-Peptides - metabolism | Amyloid beta-Peptides - cerebrospinal fluid | Mental Status Schedule | Female | Aged | Alzheimer Disease - diagnostic imaging | Biomarkers - cerebrospinal fluid | Neuroimaging | Brain | Medical imaging | Statistical analysis | Neurodegenerative diseases | Memory | Cognitive ability | Positron emission | Emission | Risk | Cerebrospinal fluid | Assaying | Emissions | Boxes | Neurology | Tomography | Dementia disorders | β-Amyloid | Recall | Alzheimers disease | Alzheimer's disease | Positron emission tomography | Age
Journal Article